Cargando…

Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants

OBJECTIVES: The aim of the study was to investigate the changes in costs and outcomes after the implementation of various disease management programs (DMPs), to identify their potential determinants, and to compare the costs and outcomes of different DMPs. METHODS: We investigated the 1-year changes...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsiachristas, Apostolos, Cramm, Jane Murray, Nieboer, Anna P, Rutten-van Mölken, Maureen PMH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118650/
https://www.ncbi.nlm.nih.gov/pubmed/25089122
http://dx.doi.org/10.1186/1478-7547-12-17
_version_ 1782328875025432576
author Tsiachristas, Apostolos
Cramm, Jane Murray
Nieboer, Anna P
Rutten-van Mölken, Maureen PMH
author_facet Tsiachristas, Apostolos
Cramm, Jane Murray
Nieboer, Anna P
Rutten-van Mölken, Maureen PMH
author_sort Tsiachristas, Apostolos
collection PubMed
description OBJECTIVES: The aim of the study was to investigate the changes in costs and outcomes after the implementation of various disease management programs (DMPs), to identify their potential determinants, and to compare the costs and outcomes of different DMPs. METHODS: We investigated the 1-year changes in costs and effects of 1,322 patients in 16 DMPs for cardiovascular risk (CVR), chronic obstructive pulmonary disease (COPD), and diabetes mellitus (DMII) in the Netherlands. We also explored the within-DMP predictors of these changes. Finally, a cost-utility analysis was performed from the healthcare and societal perspective comparing the most and the least effective DMP within each disease category. RESULTS: This study showed wide variation in development and implementation costs between DMPs (range:€16;€1,709) and highlighted the importance of economies of scale. Changes in health care utilization costs were not statistically significant. DMPs were associated with improvements in integration of CVR care (0.10 PACIC units), physical activity (+0.34 week-days) and smoking cessation (8% less smokers) in all diseases. Since an increase in physical activity and in self-efficacy were predictive of an improvement in quality-of-life, DMPs that aim to improve these are more likely to be effective. When comparing the most with the least effective DMP in a disease category, the vast majority of bootstrap replications (range:73%;97) pointed to cost savings, except for COPD (21%). QALY gains were small (range:0.003;+0.013) and surrounded by great uncertainty. CONCLUSIONS: After one year we have found indications of improvements in level of integrated care for CVR patients and lifestyle indicators for all diseases, but in none of the diseases we have found indications of cost savings due to DMPs. However, it is likely that it takes more time before the improvements in care lead to reductions in complications and hospitalizations.
format Online
Article
Text
id pubmed-4118650
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41186502014-08-02 Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants Tsiachristas, Apostolos Cramm, Jane Murray Nieboer, Anna P Rutten-van Mölken, Maureen PMH Cost Eff Resour Alloc Research OBJECTIVES: The aim of the study was to investigate the changes in costs and outcomes after the implementation of various disease management programs (DMPs), to identify their potential determinants, and to compare the costs and outcomes of different DMPs. METHODS: We investigated the 1-year changes in costs and effects of 1,322 patients in 16 DMPs for cardiovascular risk (CVR), chronic obstructive pulmonary disease (COPD), and diabetes mellitus (DMII) in the Netherlands. We also explored the within-DMP predictors of these changes. Finally, a cost-utility analysis was performed from the healthcare and societal perspective comparing the most and the least effective DMP within each disease category. RESULTS: This study showed wide variation in development and implementation costs between DMPs (range:€16;€1,709) and highlighted the importance of economies of scale. Changes in health care utilization costs were not statistically significant. DMPs were associated with improvements in integration of CVR care (0.10 PACIC units), physical activity (+0.34 week-days) and smoking cessation (8% less smokers) in all diseases. Since an increase in physical activity and in self-efficacy were predictive of an improvement in quality-of-life, DMPs that aim to improve these are more likely to be effective. When comparing the most with the least effective DMP in a disease category, the vast majority of bootstrap replications (range:73%;97) pointed to cost savings, except for COPD (21%). QALY gains were small (range:0.003;+0.013) and surrounded by great uncertainty. CONCLUSIONS: After one year we have found indications of improvements in level of integrated care for CVR patients and lifestyle indicators for all diseases, but in none of the diseases we have found indications of cost savings due to DMPs. However, it is likely that it takes more time before the improvements in care lead to reductions in complications and hospitalizations. BioMed Central 2014-07-28 /pmc/articles/PMC4118650/ /pubmed/25089122 http://dx.doi.org/10.1186/1478-7547-12-17 Text en Copyright © 2014 Tsiachristas et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tsiachristas, Apostolos
Cramm, Jane Murray
Nieboer, Anna P
Rutten-van Mölken, Maureen PMH
Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants
title Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants
title_full Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants
title_fullStr Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants
title_full_unstemmed Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants
title_short Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants
title_sort changes in costs and effects after the implementation of disease management programs in the netherlands: variability and determinants
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118650/
https://www.ncbi.nlm.nih.gov/pubmed/25089122
http://dx.doi.org/10.1186/1478-7547-12-17
work_keys_str_mv AT tsiachristasapostolos changesincostsandeffectsaftertheimplementationofdiseasemanagementprogramsinthenetherlandsvariabilityanddeterminants
AT crammjanemurray changesincostsandeffectsaftertheimplementationofdiseasemanagementprogramsinthenetherlandsvariabilityanddeterminants
AT nieboerannap changesincostsandeffectsaftertheimplementationofdiseasemanagementprogramsinthenetherlandsvariabilityanddeterminants
AT ruttenvanmolkenmaureenpmh changesincostsandeffectsaftertheimplementationofdiseasemanagementprogramsinthenetherlandsvariabilityanddeterminants